GLUCOPHAGE® (metformin hydrochloride) Notification to HCPs and Patients

 

GLUCOPHAGE® (metformin hydrochloride) was previously commercialized by Bristol-Myers Squibb (BMS) in the U.S., and BMS has decided to discontinue commercialization. Merck KGaA, Darmstadt, Germany licensed to BMS the rights to the product when it was originally approved in the U.S.; today, the rights to GLUCOPHAGE are in the process of transferring to EMD Serono in the U.S.
 
Due to the company’s strategic focus and resourcing, EMD Serono decided not to commercialize GLUCOPHAGE in the U.S. at this time. Patients currently taking GLUCOPHAGE should speak directly with their healthcare team about the treatment plan that best meets their needs.
 
As the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, we are focused exclusively on specialty care conditions including multiple sclerosis, oncology, fertility and HIV-associated wasting. We continue to explore and seek to develop potential new medicines in oncology, immuno-oncology, neurology and immunology.

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Site Exit Disclaimer

You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.

If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website. 

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement